Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALTB-268 · 1 trial · 1 indication
Adverse events (AEs) - severity of the AEs will be graded using the most current version of the Common Terminology Criteria for AE (CTCAE) (V5.0) 5-point scale. The relationship between AEs and the study drug will be indicated as related or not related.
| Arm | Type | Description |
|---|---|---|
| ALTB-268 | EXPERIMENTAL | Subcutaneous dose in healthy volunteers |
| Placebo | PLACEBO_COMPARATOR | Subcutaneous dose in healthy volunteers |
| Name | Type | Description |
|---|---|---|
| ALTB-268 | BIOLOGICAL | monoclonal antibody |
| Placebo | OTHER | formulation buffer |
Inclusion Criteria: 1. Written Informed Consent and willingness to comply with the study restrictions. 2. Sex: male or female volunteers. 3. Age: 18 to 55 years, inclusive, at screening. 4. Body mass index (BMI): 18.0 to 32.0 kg/m2, inclusive, at screening. 5. Weight: 50 kg to 110 kg, inclusive, at...
ALTB-268 is an investigational monoclonal antibody being developed by Icon Plc (ticker: ICLR). It is currently in Phase 1 clinical development and has been studied in healthy volunteers. The drug is administered subcutaneously and is being evaluated for its safety, tolerability, pharmacokinetics, and pharmacodynamics.
The specific molecular target of ALTB-268 has not been disclosed. As a monoclonal antibody, it is designed to bind to a specific protein, but the exact target is not publicly available at this time.
ALTB-268 is being developed by Icon Plc, a company publicly traded under the ticker ICLR. Icon Plc is the sponsor of the clinical trials for this investigational drug.
ALTB-268 is in Phase 1 clinical development. It has completed one Phase 1 trial in healthy volunteers. The drug is investigational and has not been approved by regulatory authorities for any indication.
ALTB-268 has been studied in one completed Phase 1 trial, identified as NCT05723692. This first-in-human study evaluated single ascending doses and multiple ascending doses of subcutaneously administered ALTB-268 in healthy volunteers in the United States. The trial enrolled 56 participants.
No alternative names for ALTB-268 have been disclosed. The drug is known only by its code name ALTB-268 in clinical trial registries and public information.